AI CuratorAI-generated
Research summary · AI summary · not yet reviewedHuman studyCase reportPublished in a peer-reviewed journal
Case Report of a 30-Year-Old Black Woman with Relapsing MS Post-Ofatumumab Treatment
A 30-year-old woman with relapsing MS experienced a relapse 4 months after interrupting ofatumumab treatment. Her symptoms improved with intravenous steroids, and she remained stable after resuming ofatumumab.
- Tags
- #MSResearch
- Most relevant to
- —
This plain-English summary was written by AI from a published abstract and may contain errors. It is not medical advice. Read the original study and talk to your MS team before making decisions about treatment.
- Human efficacy
- Not established from this source
- Mechanism
- Not reported
- Evidence strength
- Limited
- Outcome
- Not reported
Why it matters
This case highlights the potential impact of treatment interruption in MS management and suggests that ofatumumab may have sustained benefits upon reintroduction.
What this does not prove
This is a single case report; therefore, it does not establish causality and results are limited to one patient's experience.
Next milestone
No next milestone was established from the available source.
Study facts
- Study design
- Case report
- Participants / samples
- Not reported
- Randomised
- Not reported
- Controlled
- Not reported
- Primary endpoint met
- Not reported
- Relevant MS type
- Not reported
- Publication date
- 2026-03-30
- Evidence reviewed
- Abstract only
- Regulatory approval
- Not reported
- Research areas
- Not classified
- Biological target
- Not reported
- Pathway
- Not reported
- Population
- 30-year-old Black woman with relapsing MS
- Size of effect
- Not reported
- Secondary endpoints
- Not reported
- MRI endpoints
- Not reported
- Biomarkers
- Not reported
- Safety
- Not reported
Original sources
- Primary evidenceOfatumumab Interruption Results in Disease Reactivation: A Case Report. ↗DOI: 10.7224/1537-2073.2025-012
Supporting passages (8)
study designPublication types: Case Reports; Journal Article
findingsHer symptoms improved with intravenous steroid treatment.
findingsAfter restarting ofatumumab, she remained clinically and radiologically stable.
populationWe present the case of a 30-year-old Black woman with relapsing MS who did well on ofatumumab for several years before her treatment was interrupted, leading to a relapse 4 months later.
publication datePublication date: 2026-03-30
limitationsTitle: Ofatumumab Interruption Results in Disease Reactivation: A Case Report.
peer reviewedPublication types: Case Reports; Journal Article
subjectsPublication types: Case Reports; Journal Article
AI assessment, not yet reviewed by a person · version 1 · Community votes are separate from evidence review.